Introduction
============

Ovarian clear cell carcinoma (OCCC) is the fourth most common of histologic types of epithelial ovarian cancer (EOC). OCCC prognosis is similar to other histologic types in early-stage disease but it has the worst prognosis in advanced stage disease \[[@b1-crt-2014-324]\]. In general, about two-thirds of patients with EOC including OCCC have advanced stage disease at diagnosis because the disease is typically symptomless and there is no effective screening method \[[@b2-crt-2014-324]\], resulting in 5-year survival of 18.6% in patients with advanced-stage disease \[[@b1-crt-2014-324]\]. To monitor tumor response and confirm relapse in patients with EOC, cancer antigen 125 (CA-125) levels are a highly useful surrogate in the clinical setting \[[@b3-crt-2014-324]\].

However, the prognostic value of CA-125 levels is less clear in OCCC. A limited number of studies found that CA-125 levels were lower in OCCC than in other histologic types, and did not reflect clinical outcomes of patients with OCCC \[[@b4-crt-2014-324],[@b5-crt-2014-324]\]. To overcome these limitations, there is a growing interest in systemic inflammatory response (SIR) markers such as leukocyte differential counts to predict clinical outcomes in patients with EOC, because various types of malignancy are associated with systemic inflammation, which may contribute to secondary hematologic abnormalities \[[@b6-crt-2014-324],[@b7-crt-2014-324]\]. SIR markers, including neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR), and platelet to lymphocyte ratio (PLR), may be useful to predict clinical outcomes in patients with EOC \[[@b8-crt-2014-324],[@b9-crt-2014-324]\]. Nevertheless, most pertinent studies included different histologic types of EOC, while there is a lack of studies where the efficacy of SIR markers was investigated in patients with OCCC. Thus, we conducted the current study to compare the predictive and prognostic values among leukocyte differential counts, SIR markers and CA-125 levels, and thereby to identify the most useful marker in patients with OCCC.

Materials and Methods
=====================

1. Study population
-------------------

We collected clinico-pathologic data from a database of EOC registered from Seoul National University Hospital and Seoul National University Bundang Hospital between February 1997 and December 2012. The Institutional Review Board at our institution approved the current study, and the informed consent requirement was waived because the current study was conducted by a retrospective medical record review.

We included only patients with OCCC who underwent primary debulking surgery. Leukocyte differential counts including neutrophil, lymphocyte, monocyte, platelet, basophil, and eosinophil, SIR markers such as NLR, MLR, and PLR, CA-125 levels were measured within one week before staging laparotomy. However, patients with any inflammatory conditions or other malignancies that could affect the results of laboratory tests were excluded, except endometriosis proved by biopsy. Clinico-pathologic data collected included age, International Federation of Gynecology and Obstetrics (FIGO) stage, endometriosis, extent of debulking surgery, regimen and cycles of adjuvant chemotherapy, leukocyte differential counts, SIR markers, CA-125 levels, tumor response, platinum-resistance, progression-free survival (PFS), and overall survival (OS).

2. Data extraction
------------------

Leukocyte differential counts were estimated 1 week prior to surgery (SYSMEX XE-2100, TOA Medical Electronics, Kobe, Japan), and CA-125 levels were measured at the same time using a radioimmunoassay kit (Fujirebio Diagnostics, Malvern, PA). Optimal debulking was defined as a residual tumor ≤ 1 cm in a maximal diameter, and complete response (CR) was defined as the disappearance of all tumor burdens for at least 4 weeks with normalization of CA-125 levels. PFS was calculated as the time elapsed from the date of completion of primary treatment to the date of clinically proven recurrence, and platinum-resistance was defined as PFS less than 6 months. OS was defined as the length of time from the date of surgery to the date of cancer-related death or the end of study.

3. Statistical analysis
-----------------------

We compared leukocyte differential counts, SIR markers and CA-125 levels based on clinico-pathologic characteristics using Student's t test and Mann-Whitney U test in patients with OCCC, and selected potential markers associated with the clinico-pathologic characteristics among them. We calculated the best cut-off values of potential markers based on the receiver operating characteristic (ROC) curve, and assessed the sensitivity (SN), specificity (SP), positive predictive value (PPV), negative predictive value (NPV), and accuracy to identify the best marker for predicting clinical outcomes.

Next, we investigated the best prognostic factors among the potential markers for tumor response and survival in the patients. To this end, we performed logistic regression and Cox's proportional hazard analyses, and calculated odds ratio (OR), hazard ratio (HR) and 95% confidence interval (CI). Statistical analyses were performed with SPSS ver. 19.0 (SPSS Inc., Chicago, IL). We rejected null hypotheses of no difference if p-values were less than 0.05, or, equivalently, if the 95% CIs of risk point estimates excluded 1.

Results
=======

1. Patient characteristics
--------------------------

One hundred and nine patients with OCCC were included, and [Table 1](#t1-crt-2014-324){ref-type="table"} shows their clinico-pathologic characteristics. The median age was 53 years (range, 30 to 86 years), and the median duration of follow-up was 46 months (range, 6.1 to 192.9 months). One hundred and one patients (92.6%) had pure OCCC, whereas, of those with mixed OCCC, three (2.8%) had endometrioid and serous types, three (2.8%) endometrioid type, and two (1.8%) serous type in addition to clear cell carcinoma. After primary treatment, 89 patients (81.7%) showed CR while four (3.7%) demonstrated partial response, two (1.8%) had stable disease, and 14 (12.8%) suffered disease progression.

2. Prediction
-------------

When we compared leukocyte differential counts, SIR markers and CA-125 levels based on clinico-pathologic characteristics, neutrophila, monocytosis, thrombocytosis, elevated NLR, PLR, and CA-125 levels were associated with advanced-stage disease, non-CR, and platinum-resistance. Thrombocytosis, elevated NLR, PLR, and CA-125 levels were associated with suboptimal debulking, and elevated MLR was associated with non-CR and platinum-resistance ([Table 2](#t2-crt-2014-324){ref-type="table"}). We calculated the best cut-off values of the potential markers selected in [Table 2](#t2-crt-2014-324){ref-type="table"} by ROC curves, and assessed SN, SP, PPV, NPV, and accuracy ([Fig. 1](#f1-crt-2014-324){ref-type="fig"}). CA-125 levels were best at predicting advanced-stage disease (≥ 46.5 U/mL), suboptimal debulking (≥ 11.45 U/mL) and platinum-resistance (≥ 66.4 U/mL), while PLR ≥ 205.4 predicted non-CR most accurately ([Table 3](#t3-crt-2014-324){ref-type="table"}).

3. Prognosis
------------

To determine the best prognostic factors among the potential markers, we performed logistic regression analyses, which showed that optimal debulking (adjusted OR, 0.02; 95% CI, 0.01 to 0.12) and PLR \< 205.4 (adjusted OR, 0.17; 95% CI, 0.04 to 0.69) were independent factors associated with the reduced risk of non-CR ([Table 4](#t4-crt-2014-324){ref-type="table"}). In terms of survival, early-stage disease, optimal debulking, taxane- and platinum-based chemotherapy and NLR \< 2.8 were favorable factors for improved PFS (adjusted HRs, 0.18, 0.37, 0.36, and 0.49; 95% CIs, 0.08 to 0.41, 0.16 to 0.84, 0.15 to 0.89, and 0.25 to 0.99) while early-stage disease and optimal debulking were favorable factors for improved OS (adjusted HRs, 0.08 and 0.26; 95% CIs, 0.03 to 022 and 0.09 to 0.75) ([Table 5](#t5-crt-2014-324){ref-type="table"}).

Discussion
==========

SIR involves secondary changes in the levels of circulating leukocytes, which show neutrophilia, monocytosis, lymphocytopenia and thrombocytosis \[[@b10-crt-2014-324]\]. Thus, some leukocyte differential counts and SIR markers have been studied in relation with EOC because leukocyte-mediated inflammatory cytokines by tumor would inhibit apoptosis and promote angiogenesis, resulting in tumor growth, progression and metastasis \[[@b11-crt-2014-324]\]. In particular, neutrophilia, lymphocytopenia, NLR and PLR are prognostic of advance-stage disease, residual disease after surgery and survival in patients with EOC-like CA-125 levels \[[@b12-crt-2014-324]-[@b16-crt-2014-324]\].

In the current study, CA-125 levels were best for predicting advanced-stage disease, suboptimal debulking and platinum-resistance in patients with OCCC. Although most leukocyte differential counts and SIR markers were statistically significant for predicting advanced-stage disease, suboptimal debulking and platinum-resistance, we found that CA-125 levels had the highest SN, SP, PPV, NPV, and accuracy. Specific leukocyte differential counts (neutrophil, monocyte, and platelet), and SIR markers (NLR, MLR, and PLR) increase proportionally with a growing burden of inflammation such as cancer, whereas CA-125 levels are relatively low in early-stage OCCC in comparison with other histologic types of EOC because of the apparent initial smaller volume of disease as well as fundamental differences in the biology of malignancy \[[@b4-crt-2014-324],[@b12-crt-2014-324],[@b17-crt-2014-324]\]. However, CA-125 levels increase in advanced-stage disease because of an increase of tumor burden \[[@b18-crt-2014-324]\]. Thus, high levels of CA-125 can predict advanced-stage disease or suboptimal debulking more accurately compared with elevation of specific leukocyte differential counts and SIR markers. This hypothesis is supported indirectly by a study that found CA-125 levels to be a sensitive biomarker of tumor response in low-grade serous carcinoma showing a low level of CA-125 \[[@b19-crt-2014-324]\].

Furthermore, PLR was the most significant to predict tumor response after primary treatment among the potential markers. Platelets interact with tumor cells, and to contain factors contributing to tumor growth, invasion and angiogenesis \[[@b20-crt-2014-324]\]. Moreover, it can protect tumor cells from natural killer cell-mediated lysis, thereby facilitating metastasis \[[@b21-crt-2014-324]\]. Thus, thrombocytosis is also common in patients with EOC \[[@b13-crt-2014-324]\]. Since tumor cells secret thrombopoietic cytokines such as interleukin-6, thrombocytosis is related to poor response in solid tumors, combined with lymphocytopenia \[[@b22-crt-2014-324]\]. In the current study, we found PLR, among the potential markers, to be a better predictor of risk of non-CR in patients with OCCC, like previous studies \[[@b9-crt-2014-324],[@b13-crt-2014-324]\]. However, all potential markers have modest predictive values to determine tumor response in patients with OCCC because common mechanisms lead to their coincident elevation. Thus, more focused studies are required to validate the role of PLR to predict tumor response in the patients.

Last, NLR was the most important prognostic factor for PFS despite there being no marker related to OS among the potential markers. Many studies reports that a higher neutrophil count or a lower lymphocyte predicts poorer survival in EOC \[[@b12-crt-2014-324]\]. Among blood components, the potential mechanism underlying the prognostic value of NLR may be an association between high NLR and inflammation. Neutrophilia produces inflammatory cytokines and chemokines by both the tumor and associated host cells such as leukocytes, and contributes to malignant progression by secreting tumor growth factors such as vascular endothelial growth factor \[[@b11-crt-2014-324]\]. However, neutrophilia as an inflammatory response by cancer inhibits the immune system by suppressing the cytotoxic activity of immune cells such as lymphocytes and natural killer cells \[[@b23-crt-2014-324]\]. NLR reflects these inflammatory changes, and therefore may be a useful marker in patients with a cancer for which reliable biomarkers are lacking \[[@b24-crt-2014-324]\]. A recent meta-analysis reported a similar result in that NLR was related to a higher risk of mortality than PLR in solid tumors because the broader properties of neutrophils, in comparison with platelets, may stimulate various cytokines \[[@b25-crt-2014-324]\]. Nevertheless, no potential markers have a significant impact on OS in the current study, which requires a new biomarker for predicting OS in the patients.

Whether the potential markers can be applied to predict clinical outcomes in patients with OCCC is controversial. Although recent meta-analyses emphasized the importance of SIR markers to predict prognosis of solid tumors, research that interprets their usefulness in EOC when compared with other malignancies is lacking \[[@b24-crt-2014-324],[@b25-crt-2014-324]\]. Furthermore, OCCC cases in most studies comprise a small proportion, 5%-8%, among patients with EOC, making it difficult to evaluate prognostic values of the potential markers in patients with OCCC \[[@b4-crt-2014-324],[@b19-crt-2014-324]\].

Conclusion
==========

Although the current study has some limitations such as a retrospective design and unassessed possible confounders affecting SIR (e.g., smoking or oral contraceptive use) \[[@b12-crt-2014-324]\], we included a large number of patients with OCCC, and sought to identify the most dominant markers related to clinical outcomes by stepwise comparison of prognostic values among the potential markers. Conclusively, CA-125 levels may be the most useful marker for predicting advanced-stage disease, suboptimal debulking and platinum-resistance, and PLR and NLR may be the most effective to predict non-CR and PFS in patients with OCCC.
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###### 

Clinico-pathologic characteristics of 109 patients with ovarian clear cell carcinoma

  Characteristic             No. of patients (%)
  -------------------------- ---------------------
  Age (yr)                   
   \< 54                     57 (52.3)
   ≥ 54                      52 (47.7)
  FIGO stage                 
   I-II                      68 (62.4)
   III-IV                    41 (37.5)
  Histology                  
   Pure                      101 (92.6)
   Mixed                     8 (7.4)
  Endometriosis              
   No                        62 (56.9)
   Yes                       47 (43.1)
  Optimal debulking          
   No                        95 (87.2)
   Yes                       14 (12.8)
  Regimen of chemotherapy    
   No                        6 (5.5)
   Non-taxane and platinum   17 (15.6)
   Taxane and platinum       86 (78.9)
  Cycles of chemotherapy     
   ≤ 6                       93 (85.3)
   6-9                       16 (14.7)
  Platinum-resistance        
   No                        89 (81.7)
   Yes                       20 (18.3)
  Tumor response             
   Non-CR                    20 (18.3)
   CR                        89 (81.7)

FIGO, International Federation of Gynecology and Obstetrics; CR, complete response.

###### 

Leukocyte differential counts, systemic inflammatory response markers, and CA-125 levels based on clinico-pathologic characteristics of 109 patients with ovarian clear cell carcinoma

  Characteristic        Leukocyte differential counts                                SIR markers   CA-125 (U/mL)                                                                                                                                                                                                                                                                                                      
  --------------------- ------------------------------------------------------------ ------------- -------------------------------------------------------- ------- --------- -------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------------ --------------------------------------------------------------
  Age (yr)                                                                                                                                                                                                                                                                                                                                                                                                            
   \< 54                4,481±1,863                                                  1,691±713     396±189                                                  27±17   109±107   308±100                                                  3.1+1.7                                                  0.3±0.1                                                  206.4±103.7                                                  163.1±436.7
   ≥ 55                 4,355±1,729                                                  1,715±532     381±151                                                  26±16   133±106   318±95                                                   2.9±1.7                                                  0.2±0.1                                                  204±93                                                       412.9±1,270.8
  FIGO stage                                                                                                                                                                                                                                                                                                                                                                                                          
   I-II                 4,019±1,403[^a)^](#tfn1-crt-2014-324){ref-type="table-fn"}   1,787±718     359±152[^a)^](#tfn1-crt-2014-324){ref-type="table-fn"}   24±16   130±109   287±75[^a)^](#tfn1-crt-2014-324){ref-type="table-fn"}    2.6±1.4[^a)^](#tfn1-crt-2014-324){ref-type="table-fn"}   0.2±0.1[^a)^](#tfn1-crt-2014-324){ref-type="table-fn"}   181.3±80.4[^a)^](#tfn1-crt-2014-324){ref-type="table-fn"}    110.8±378.2[^a)^](#tfn1-crt-2014-324){ref-type="table-fn"}
   III-IV               5,100±2,162                                                  1,561±422     440±193                                                  27±16   102±104   355±115                                                  3.5±1.9                                                  0.3±0.2                                                  245.7±112.8                                                  565.4±1,412.8
  Histology                                                                                                                                                                                                                                                                                                                                                                                                           
   Pure                 4,473±1,820                                                  1,722±642     386±174                                                  26±17   115±98    315±99                                                   3.0±1.7                                                  0.2±0.1                                                  204.9±98.6                                                   279.7±961.8
   Mixed                3,724±1,275                                                  1,449±426     439±141                                                  18±8    182±191   274±49                                                   3.0±2.1                                                  0.3±0.2                                                  210.1±102.2                                                  329.1±648.3
  Endometriosis                                                                                                                                                                                                                                                                                                                                                                                                       
   No                   4,573±1,930                                                  1,685±710     398±184                                                  24±16   107±103   316±97                                                   3.2±1.8                                                  0.3±0.2                                                  209.2±88.6                                                   411±1212
   Yes                  4,214±1,586                                                  1,725±513     376±154                                                  26±17   137±111   307±99                                                   2.7±1.4                                                  0.2±0.1                                                  199.8±111.1                                                  117.8±298.9
  Optimal debulking                                                                                                                                                                                                                                                                                                                                                                                                   
   Yes                  4,207±1,494                                                  1,710±661     381±159                                                  25±16   127±112   297±83[^a)^](#tfn1-crt-2014-324){ref-type="table-fn"}    2.8±1.6[^a)^](#tfn1-crt-2014-324){ref-type="table-fn"}   0.3±0.1                                                  196±93[^a)^](#tfn1-crt-2014-324){ref-type="table-fn"}        166.3±439.8[^a)^](#tfn1-crt-2014-324){ref-type="table-fn"}
   No                   5,890±2,831                                                  1,653±387     448±243                                                  30±19   72±34     419±120                                                  3.8±2.3                                                  0.3±0.2                                                  270±114                                                      1,069.8±2,263.3
  Tumor response                                                                                                                                                                                                                                                                                                                                                                                                      
   Non-CR               5,644±2,419[^a)^](#tfn1-crt-2014-324){ref-type="table-fn"}   1,502±354     476±221[^a)^](#tfn1-crt-2014-324){ref-type="table-fn"}   26±17   91±54     401±118[^a)^](#tfn1-crt-2014-324){ref-type="table-fn"}   3.9±1.8[^a)^](#tfn1-crt-2014-324){ref-type="table-fn"}   0.3±0.1[^a)^](#tfn1-crt-2014-324){ref-type="table-fn"}   283.7±111.3[^a)^](#tfn1-crt-2014-324){ref-type="table-fn"}   781.1±1,931.5[^a)^](#tfn1-crt-2014-324){ref-type="table-fn"}
   CR                   4,142±1,500                                                  1,748±673     370±154                                                  25±16   126±115   292±79                                                   2.8±1.6                                                  0.2±0.1                                                  187.3±86.2                                                   170.3±449.4
  Platinum-resistance                                                                                                                                                                                                                                                                                                                                                                                                 
   Yes                  5,352±1,827[^a)^](#tfn1-crt-2014-324){ref-type="table-fn"}   1,552±473     461±180[^a)^](#tfn1-crt-2014-324){ref-type="table-fn"}   24±16   124±119   363±114[^a)^](#tfn1-crt-2014-324){ref-type="table-fn"}   3.7±1.8[^a)^](#tfn1-crt-2014-324){ref-type="table-fn"}   0.3±0.2[^a)^](#tfn1-crt-2014-324){ref-type="table-fn"}   259.2±120.9[^a)^](#tfn1-crt-2014-324){ref-type="table-fn"}   720.7±1,925.7[^a)^](#tfn1-crt-2014-324){ref-type="table-fn"}
   No                   4,209±1,727                                                  1,737±661     373±167                                                  25±16   119±105   301±90                                                   2.8±1.6                                                  0.2±0.1                                                  192.9±88.7                                                   184±471.9

CA-125, cancer antigen 125; SIR, systemic inflammatory response; NLR, neutrophil to lymphocyte ratio; MLR, monocyte to lymphocyte ratio; PLR, platelet to lymphocyte ratio; FIGO, International Federation of Gynecology and Obstetrics; CR, complete response.

p \< 0.05.

###### 

SN, SP, PPV, NPV, and accuracy of leukocyte differential counts, systemic inflammatory response markers, CA-125 levels by the receiver operating characteristic curve

  Characteristic              Cut-off value   AUC    SN (%)   SP (%)   PPV (%)   NPV (%)   Accuracy (%)   p-value
  --------------------------- --------------- ------ -------- -------- --------- --------- -------------- ---------
  FIGO stage III-IV disease                                                                               
   Neutrophil (cell/μL)       ≥ 4,370         0.66   60.5     59.4     46.9      71.7      59.8           \< 0.01
   Monocyte (cell/μL)         ≥ 389           0.65   65.8     64.6     52.1      76.4      65             0.01
   Platelet (×10^3^/μL)       ≥ 300           0.70   60.5     57.8     46        71.2      58.8           \< 0.01
   NLR                        ≥ 2.4           0.65   60.5     56.3     45.1      70.6      57.8           0.01
   MLR                        ≥ 0.2           0.64   60.5     60       46.9      72.2      60.2           0.02
   PLR                        ≥ 178.3         0.68   60.5     57.8     46        71.2      58.8           \< 0.01
   CA-125 (U/mL)              ≥ 46.5          0.78   73.2     67.2     57.7      80.4      69.4           \< 0.01
  Suboptimal debulking                                                                                    
   Neutrophil (cell/μL)       ≥ 4,254         0.69   61.5     50.6     15.4      90        51.9           0.03
   Monocyte (cell/μL)         ≥ 354           0.54   61.5     43.3     13.6      88.6      45.6           0.65
   Platelet (×10^3^/μL)       ≥ 295           0.80   76.9     51.7     18.9      93.9      54.9           \< 0.01
   NLR                        ≥ 2.4           0.64   61.5     50.6     15.4      90        52             0.11
   MLR                        ≥ 0.2           0.56   61.5     54.4     16.3      90.7      55.3           0.49
   PLR                        ≥ 205.4         0.72   69.2     67.4     23.7      93.8      67.6           0.01
   CA-125 (U/mL)              ≥ 114.5         0.87   78.6     78.7     35.5      96.1      78.7           \< 0.01
  Non-CR                                                                                                  
   Neutrophil (cell/μL)       ≥ 4,428         0.71   68.4     62.7     29.5      89.7      63.7           \< 0.01
   Monocyte (cell/μL)         ≥ 394           0.67   63.2     63.1     27.9      88.3      66             0.03
   Platelet (×10^3^/μL)       ≥ 297           0.77   73.7     54.2     26.9      90        57.8           \< 0.01
   NLR                        ≥ 2.7           0.71   73.7     65.1     32.6      91.5      66.7           \< 0.01
   MLR                        ≥ 0.3           0.69   68.4     63.1     29.5      89.8      64.1           \< 0.01
   PLR                        ≥ 205.4         0.78   73.7     71.1     36.8      92.2      71.6           \< 0.01
   CA-125 (U/mL)              ≥ 66.9          0.76   70       69.3     34.1      69.3      69.4           \< 0.01
  Platinum-resistance                                                                                     
   Neutrophil (cell/μL)       ≥ 4,436         0.70   63.2     62.7     27.9      88.1      62.7           \< 0.01
   Monocyte (cell/μL)         ≥ 394           0.65   63.2     63.1     27.9      88.3      63.1           0.04
   Platelet (×10^3^/μL)       ≥ 297           0.67   63.2     51.8     23.1      86        53.9           0.02
   NLR                        ≥ 2.8           0.69   68.4     65.1     31        90        65.7           \< 0.01
   MLR                        ≥ 0.3           0.66   63.2     61.9     27.3      88.1      62.1           0.03
   PLR                        ≥ 178.3         0.67   68.4     55.4     26        88.5      57.8           0.02
   CA-125 (U/mL)              ≥ 66.4          0.73   70       68.2     33.3      90.9      68.5           \< 0.01

SN, sensitivity; SP, specificity; PPV, positive predictive value; NPV, negative predictive value; AUC, area under curve; FIGO, International Federation of Gynecology and Obstetrics; NLR, neutrophil to lymphocyte ratio; MLR, monocyte to lymphocyte ratio; PLR, platelet to lymphocyte ratio; CA-125, cancer antigen 125.

###### 

Prognostic factors associated with the reduced risk of non-complete response after primary treatment in 109 patients with ovarian clear cell carcinoma

  Factor                                    Univariate   Multivariate                                
  ----------------------------------------- ------------ -------------- --------- ------ ----------- ----------
  Age \< 54 yr                              0.70         0.26-1.85      0.47      \-     \-          \-
  FIGO stage I-II disease                   0.07         0.02-0.24      \< 0.01   \-     \-          \-
  Pure OCCC                                 0.65         0.12-3.49      0.62      \-     \-          \-
  Optimal debulking                         0.02         0.01-0.08      \< 0.01   0.02   0.01-0.12   \< 0.001
  Taxane- and platinum-based chemotherapy   0.61         0.16-2.29      0.46      \-     \-          \-
  \> 6 cycles of chemotherapy               0.42         0.13-1.40      0.16      \-     \-          \-
  PLR \< 205.4                              0.15         0.05-0.45      \< 0.01   0.17   0.04-0.69   0.01
  CA-125 \< 66.9 (U/mL)                     0.19         0.07-0.55      \< 0.01   \-     \-          \-

OR, odds ratio; CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; OCCC, ovarian clear cell carcinoma; PLR, platelet to lymphocyte ratio; CA-125, cancer antigen 125.

###### 

Prognostic factors related with improved progression-free and overall survivals in 109 patients with ovarian clear cell carcinoma

  Factor                                     Univariate   Multivariate                                
  ------------------------------------------ ------------ -------------- --------- ------ ----------- ---------
  Progression-free survival                                                                           
   Age \< 54 yr                              1.14         0.60-2.17      0.68      \-     \-          \-
   FIGO stage I-II disease                   0.15         0.08-0.31      \< 0.01   0.18   0.08-0.41   \< 0.01
   Pure OCCC                                 0.56         0.20-1.59      0.28      \-     \-          \-
   Optimal debulking                         0.13         0.06-0.27      \< 0.01   0.37   0.16-0.84   0.02
   Taxane- and platinum-based chemotherapy   0.87         0.41-1.84      0.72      0.36   0.15-0.89   0.03
   \> 6 cycles of chemotherapy               1.79         0.82-3.93      0.14      \-     \-          \-
   NLR \< 2.8                                0.34         0.18-0.67      \< 0.01   0.49   0.25-0.99   0.04
   CA-125 \< 68.5 (U/mL)                     0.29         0.15-0.57      \< 0.01   \-     \-          \-
  Overall survival                                                                                    
   Age \< 54 yr                              2.00         0.85-4.69      0.11      \-     \-          \-
   FIGO stage I-II disease                   0.12         0.05-0.30      \< 0.01   0.08   0.03-0.22   \< 0.01
   Pure OCCC                                 0.53         0.16-1.78      0.30      \-     \-          \-
   Optimal debulking                         0.14         0.06-0.36      \< 0.01   0.26   0.09-0.75   0.01
   Taxane- and platinum-based chemotherapy   0.69         0.29-1.65      0.40      \-     \-          \-
   \> 6 cycles of chemotherapy               3.06         1.31-7.13      0.10      \-     \-          \-
   NLR \< 2.8                                0.29         0.13-0.68      \< 0.01   \-     \-          \-
   CA-125 \< 68.5 (U/mL)                     0.26         0.11-0.59      \< 0.01   \-     \-          \-

HR, hazard ratio; CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; OCCC, ovarian clear cell carcinoma; NLR, neutrophil to lymphocyte ratio; CA-125, cancer antigen 125.
